BMS/GeneCentric Diagnostics, agreement to identify biomarkers for Opdivo

Bristol-Myers Squibb Company and GeneCentric Diagnostics announced a collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might identify some biomarkers for Opdivo (nivolumab), which may support future clinical trials. Additionally, BMS will fund the clinical development of the platform and of the GeneCentric’s new laboratory in Research Triangle Park. CSP identifies subtypes of cancer through an integrated analysis of tumor genomics. Acquiring such information allows to design more rational and better-targeted clinical trials, by identifying patient cohorts suitable to be optimally treated with the tested product. (Source Business Wire)